NewswireToday - /newswire/ -
Winston-Salem, NC, United States, 2010/09/02 - SmallCapReview a leading site for news and information on small caps, penny stocks and microcaps is adding Cardiome Pharma (Nasdaq: CRME) to its list of stocks "On the Radar".
Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system.
The Company's product pipeline primarily includes Vernakalant, which just successfully completed Phase III (ACT 5) clinical trials for the treatment of atrial fibrillation; Vernakalant (oral) that completed Phase IIa clinical trials and Phase IIb clinical trials for the treatment of atrial fibrillation; and GED-aPC, which completed Phase I clinical trials for the treatment of multiple disease states.
It has collaboration and license agreements with Merck & Co., for the development and commercialization of vernakalant; and Astellas Pharma US, Inc. to develop, make, and sell injectable formulations of vernakalant in North America.
CRME Investor Highlights Include:
Announced that the intravenous formulation of BRINAVESS has been granted marketing approval in the European Union, Iceland and Norway for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.Recorded net income of $4.6 million ($0.08 per common share) for the three months ended June 30, 2010.
Total revenue for Q2-2010 was $12.4 million, an increase of $5.1 million from $7.3 million in Q2-2009.
At June 30, 2010, the Company had cash and cash equivalents of $57.7 million.
To learn more about CRME visit SmallCapReview.com/.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has not been compensated for its efforts with regards to Cardiome Pharma nor does it hold any shares at this time.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost.